AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 171 min read$DVA

Rodriguez Javier sold $14.5M of DVA

Rodriguez Javier (Chief Executive Officer) sold 69,407 shares of DAVITA INC. (DVA) at an average of $209.38 ($209.28–$209.50, $14.53M total) across 2 trades over 2026-06-15 to 2026-06-16.

Original reporting
SEC EDGAR · Rodriguez Javier
Published Jun 17, 2026, 10:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$DVA
Bearish
medium confidence
Mentioned
$DVA
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DVABearishLow
01

Why it matters

The only new information is the disclosed open-market sale size and pricing; there is no accompanying company performance or guidance update in the text.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a sustained repricing without additional fundamental catalysts.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says none), nor does it provide context on total compensation, prior sale cadence, or remaining holdings beyond the post-trade figure.

Relevance 7/10Novelty 6/10Timing: Filed June 17; sale executed June 15–16

Background

SEC Form 4 reports an insider transaction by DaVita’s CEO, Rodriguez Javier, including trade dates, share count, and price range.

Company-level read

Ticker impact

$DVABearishMedium confidence
Context

DaVita CEO Rodriguez Javier sold 69,407 shares in open-market transactions at about $209.28–$209.50 per share, per Form 4 filed June 17.

Expected impact

Likely limited near-term impact; any effect should fade unless follow-on selling or other news emerges.

Evidence & confidence

The disclosure is a routine Form 4 insider sale (no 10b5-1 plan stated) with a defined transaction window, but the article provides no earnings, guidance, or regulatory/operational change.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide datapoint.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; the filing does not prove negative expectations about the business.

Key entities

  • issuer
    DAVITA INC.

    Subject of the Form 4 insider transaction; CEO sold shares in June 15–16 trades.

  • insider
    Rodriguez Javier

    DaVita CEO and director who executed the open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DVA insider trading history →

Related articles

AUG 27
$DVAMedAI 8/10

Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)

Berkshire Hathaway's largest proportional holding is in DaVita (DVA), a kidney dialysis center operator, with a 45% stake. Berkshire has reduced its position from 36.1 million to 28.7 million shares since early 2025. DaVita's stock is up 56% year-to-date, with Q1 revenue of $3.4 billion and adjusted profit of $198 million. The company raised its EPS guidance to $14.10-$15.20.

fool.com2 min
AUG 8
$DVAMed

DaVita Shares Rise After TD Cowen Upgrades Stock to Buy

DaVita HealthCare Partners (NYSE:DVA) rose about 2.1% premarket after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and long-term growth. The upgrade followed DaVita’s Q2 2026 results: adjusted EPS $4.02 vs $3.92 expected, revenue about $3.55B vs estimates, while guidance stayed unchanged.

yahoo.com5 min
AUG 7
$DVAMed

Why is DaVita stock up 2% today?

DaVita HealthCare Partners (DVA) rose about 2.1% in pre-open trading after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and MOTheR trial results. The upgrade followed DaVita’s Q2 2026 beat, with adjusted EPS of $4.02 vs $3.92 and revenue of about $3.55B vs forecasts, despite flat guidance.

investing.com3 min
AUG 6
$DVAMed

DaVita Inc. Q2 2026 Earnings Call Summary

DaVita reported Q2 2026 updates on dialysis operations, citing improved patient mortality and a Medicare bundle shift that reduced reliance on OTC phosphate binders by over 50%. Revenue per treatment fell sequentially. DaVita reconfirmed 2026 adjusted operating income guidance of $2.2B and expects 2026 treatment growth at the top of 25-50 bps. FDA approval of NIPRO expanded HD dialyzers may improve supply.

yahoo.com7 min